BORDEAUX, France, May 20, 2024 /PRNewswire/ -- TreeFrog
Therapeutics will participate for the first time at the IAPRD, to
present data from their Parkinson's disease cell therapy program,
which has demonstrated excellent results with full motor recovery
at 16 weeks in preclinical studies.[1]
Parkinson's Disease is a progressive neurological disease
affecting more than 10 million people worldwide[2] with prevalence
doubling in the last 25 years.[3] The complex disease is the result
of the degeneration of specific dopamine-producing neurons in the
brain. There is a huge unmet need as current treatments provide
symptomatic relief only and medication fails to control symptoms
for nearly 75% of people.[4] Regenerative medicine and in
particular, cell therapy, holds great potential as it can replace
these lost neurons, ultimately restoring function.
"We are excited to present the data to the scientific community
at the IAPRD for the first time. Pioneering work in the 1990s using
human fetal midbrain has already demonstrated that cell therapy can
bring real clinical benefits to patients [5] and, in the last
decade, an increasing number of trials have been launched using
pluripotent stem cells as a more standardizable cell source." says
Jens Schroeder, Chief Medical
Officer, TreeFrog Therapeutics. "Cell therapy has the
potential to open an avenue for functional recovery where no
therapy options exist. The data we are presenting reports on the
first bioproduction of a cell therapy for the disease in a scalable
bioreactor. In pre-clinical models, full behavioral recovery was
observed by 16 weeks post transplantation and dopaminergic neurons
were seen projecting into the host striatum."
The off-the-shelf therapy in development by TreeFrog uses their
proprietary technology, C-Stem™, a breakthrough technology that
addresses critical challenges of producing high quality, cell
therapies at scale, efficiently. The closed system enables both the
amplification and differentiation of cells. The Parkinson's program
is the first application of this technology using induced
pluripotent stem cells (iPSC) that are differentiated into
ready-to-graft 3D microtissues containing mature dopaminergic
neurons.
Details of presentation:
Guided poster tour - PD Therapy #P_03 (GPT)
Date & time: 20 May 2024 @
15:30-16:30
www.treefrog.fr
[1] Data on file. Poster #P_03 (GPT) IAPRD 2024
[2] Statistics | Parkinson's Foundation
[3] Parkinson disease (who.int)
[4] www.parkinsons.org.uk
[5] Lindvall et al 1989, Lindvall et al 1990, Freed et al
1992
Logo -
https://mma.prnewswire.com/media/2272329/treefrog_Logo.jpg
Chief Communications Officer
TreeFrog Therapeutics
Rachel Mooney
Rachel.mooney@treefrog.fr
View original
content:https://www.prnewswire.co.uk/news-releases/treefrog-presents-data-from-their-parkinsons-disease-cell-therapy-program-at-the-29th-world-congress-on-parkinsons-disease-and-related-disorders-iaprd-in-lisbon-302148037.html